10/ 088,852

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	4	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	5	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	6	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS	7	MAR 02	GBFULL: New full-text patent database on STN
NEWS	8	MAR 03	REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS	9	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	10	MAR 22	KOREAPAT now updated monthly; patent information enhanced
NEWS	11	MAR 22	Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS	12	MAR 22	PATDPASPC - New patent database available
NEWS	13	MAR 22	REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS	14	APR 04	EPFULL enhanced with additional patent information and new fields
NEWS	15	APR 04	EMBASE - Database reloaded and enhanced
NEWS	16	APR 18	New CAS Information Use Policies available online
NEWS	17	APR 25	Patent searching, including current-awareness alerts (SDIs), based on application date in CA/CAplus and USPATFULL/USPAT2 may be affected by a change in filing date for U.S. applications.
NEWS	18	APR 28	Improved searching of U.S. Patent Classifications for U.S. patent records in CA/CAplus
NEWS	19	MAY 23	GBFULL enhanced with patent drawing images
NEWS	20	MAY 23	REGISTRY has been enhanced with source information from CHEMCATS
NEWS	21	MAY 26	STN User Update to be held June 6 and June 7 at the SLA 2005 Annual Conference

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:19:04 ON 03 JUN 2005

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:19:14 ON 03 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 JUN 2005 HIGHEST RN 851586-61-3
DICTIONARY FILE UPDATES: 2 JUN 2005 HIGHEST RN 851586-61-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10088852.str



chain nodes :
11 19 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17
chain bonds :
7-11 11-12 19-20 20-21 21-22
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
exact/norm bonds :
7-11 11-12 21-22
exact bonds :
19-20 20-21
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17

G1:O,S,N,SO2

Hydrogen count :
9:= exact 1
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 17:19:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 23311 TO ITERATE

100.0% PROCESSED 23311 ITERATIONS 76 ANSWERS
SEARCH TIME: 00.00.01

L2 76 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	161.54

FILE 'CAPLUS' ENTERED AT 17:19:45 ON 03 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 3 Jun 2005 VOL 142 ISS 24
FILE LAST UPDATED: 2 Jun 2005 (20050602/ED)

10/ 088,852

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 4 L2

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:120821 CAPLUS
DOCUMENT NUMBER: 140:163886
TITLE: Preparation of 4-anilino substituted quinazolines as inhibitors of epidermal growth factor receptor kinases
INVENTOR(S): Gazit, Aviv; Levitzki, Alexander
PATENT ASSIGNEE(S): Yissum Research Development Company of the Hebrew University of Jerusalem, Israel
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004013091	A2	20040212	WO 2003-IL632	20030731
WO 2004013091	A3	20040729		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-399736P P 20020801
OTHER SOURCE(S): MARPAT 140:163886
GI



I



II

AB Title compds. I [R1 = (un)substituted Ph, naphthyl, etc.; R2 = H, halo, phenylamino, etc.; R3 = H, alkoxy, NO2, etc.; n = 1-3] are prepared For instance, 4-chloro-6-methylquinazoline is reacted with 2-aminophenol (EtOH, reflux, 1 h) to give II. I are potent inhibitors of protein tyrosine (PTK) kinase activity, particularly epidermal growth factor receptor (EGFR) kinase activity. I are useful in treating a variety of PTK related disorders such as cell proliferative disorders, fibrotic disorders, metabolic disorders and cancer.

IT **655248-61-6P**, 3-[2-Bromo-4-((6,7-dimethoxyquinazoline-4-yl)amino)phenyl]-2-cyano-N-[2-(3,4-dimethoxyphenyl)ethyl]acrylamide **655248-62-7P**, N-Benzyl-3-[2-bromo-4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl]-2-cyanoacrylamide **655248-63-8P**, 3-[2-Bromo-4-((6,7-dimethoxyquinazolin-4-yl)amino)phenyl]-2-cyano-N-(4-

phenylbutyl)acrylamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-anilino substituted quinazolines as inhibitors of epidermal growth factor receptor kinases)

RN 655248-61-6 CAPLUS
CN 2-Propenamide, 3-[2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-cyano-N-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 655248-62-7 CAPLUS
CN 2-Propenamide, 3-[2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-cyano-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 655248-63-8 CAPLUS
CN 2-Propenamide, 3-[2-bromo-4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-2-cyano-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:228866 CAPLUS
DOCUMENT NUMBER: 134:266317
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John; Jung, Frederic Henri; Brewster, Andrew George
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 306 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021596	A1	20010329	WO 2000-GB3580	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384291	AA	20010329	CA 2000-2384291	20000918
BR 2000014116	A	20020521	BR 2000-14116	20000918
EP 1218354	A1	20020703	EP 2000-960840	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509499	T2	20030311	JP 2001-524975	20000918
EE 200200119	A	20030415	EE 2002-119	20000918
BG 106492	A	20030131	BG 2002-106492	20020307
ZA 2002002234	A	20030619	ZA 2002-2234	20020319
NO 2002001399	A	20020430	NO 2002-1399	20020320

PRIORITY APPLN. INFO.:	GB 1999-22154	A	19990921
	GB 1999-22170	A	19990921
	WO 2000-GB3580	W	20000918

OTHER SOURCE(S): MARPAT 134:266317
GI



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO2, NH, or NR12; R12 = H or alkyl; R1-R4 = independently halo, CN, NO2, alkylsulfanyl, N(OH)R13, or R15X1; R13 = H or alkyl; X1 = a direct bond, O, CH2, OC(O), CO, CO2, S, SO, SO2, or (un)substituted NHCO, CONH, SO2NH, NHSO2, or NH; R15 = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; R5 = NHCO2R9, NHCOR9, NHSO2R9, COR9, CO2R9, SOR9, SO2OR9, CONR10R11, SONR10R11, or SO2NR10R11; R9-R11 = independently H or (un)substituted hydrocarbyl or heterocyclyl; or R10 and R11 together with the N to which they are attached = (un)substituted heterocyclyl; R6 = H or (un)substituted hydrocarbyl or heterocyclyl; R7 and R8 = independently H, halo, alkyl, (di)alkoxy(methyl), alkanoyl, CF3, CN, NHY2, alkenyl, alkynyl, or (un)substituted Ph, PhCH2, or heterocyclyl; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, a 7-step sequence involving (1) alkylation of morpholine with 1-bromo-3-chloropropane (49%), (2) addition of Et vanillate to yield Et 3-methoxy-4-(3-morpholinopropoxy)benzoate (100%), (3) nitration (86%), (4) reduction to the amine using 10% Pd/C (100%), (5) cycloaddn. with formamide to form the quinazoline(68%), (6) chlorination to give 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline (60%), and (7) amination with N-benzoyl-4-aminoaniline (58%) yielded II. The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.0193 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 1.06 μM and reduced BrdU incorporation into cellular DNA by 50% at 0.159-0.209 μM.

IT **331776-88-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 331776-88-6 CAPLUS

CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:228865 CAPLUS
DOCUMENT NUMBER: 134:266316
TITLE: Preparation of quinazoline derivatives, method of preparation and use in inhibiting aurora 2 kinase
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021595	A1	20010329	WO 2000-GB3562	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384284	AA	20010329	CA 2000-2384284	20000918
BR 2000014136	A	20020521	BR 2000-14136	20000918
EP 1218357	A1	20020703	EP 2000-962682	20000918
EP 1218357	B1	20050406		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509498	T2	20030311	JP 2001-524974	20000918
EE 200200148	A	20030415	EE 2002-148	20000918
AT 292628	E	20050415	AT 2000-962682	20000918
ZA 2002001831	A	20030605	ZA 2002-1831	20020305
NO 2002001395	A	20020515	NO 2002-1395	20020320
BG 106535	A	20021229	BG 2002-106535	20020320

PRIORITY APPLN. INFO.: GB 1999-22173 A 19990921
WO 2000-GB3562 W 20000918

OTHER SOURCE(S): MARPAT 134:266316
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB I or a salt, ester, amide or prodrug thereof, a method for the preparation of I and the use of the claimed compds. for inhibiting aurora 2 kinase are claimed. These compds. are useful in the treatment of cancer. In I: X is O, or S, S(O) or S(O)2 or NR10 where R10 is H or C1-6 alkyl. R5 is OR11, NR12R13 or SR11 where R11, R12 and R13 are independently optionally substituted hydrocarbyl or optionally substituted heterocyclic groups, and R12 and R13 may addnl. form together with the N atom to which they are attached, an optionally substituted aromatic or nonarom. heterocyclic ring which may contain further heteroatoms. R6 and R7 are independently H or hydrocarbyl. R8 and R9 are independently H, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxymethyl, di(C1-4alkoxy)methyl, C1-4 alkanoyl, trifluoromethyl, cyano, amino, C2-5 alkenyl, C2-5 alkynyl, a Ph group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms,

selected independently from O, S and N, which heterocyclic group may be aromatic or nonarom. and may be saturated (linked via a ring C or N atom) or unsatd. (linked via a ring C atom), and which Ph, benzyl or heterocyclic group may bear on one or more ring C atoms up to 5 substituents selected from hydroxy, halo, C1-3 alkyl, C1-3 alkoxy, C1-3 alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C2-4 alkanoyl, C1-4 alkanoylamino, C1-4 alkoxycarbonyl, C1-4 alkylthio, C1-4 alkylsulfinyl, C1-4 alkylsulfonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulfonyl, N-C1-4alkylaminosulfonyl, N,N-di(C1-4alkyl)aminosulfonyl, C1-4 alkylsulfonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halo, C1-3 alkyl, C1-3 alkoxy, C1-3 alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C1-4alkoxycarbonyl. R1, R2, R3, R4 are independently halo, cyano, nitro, C1-3 alkylthio, -N(OH)R14 (R14 is H, or C1-3 alkyl), or R16X1- (X1 represents a direct bond, -O-, -CH2-, -OC(O)-, -C(O)-, -S-, -SO-, -SO2-, -NR17C(O)-, -C(O)NR18-, -SO2NR19-, -NR20SO2- or -NR21- (R17, R18, R19, R20 and R21 each independently represents H, C1-3 alkyl or C1-3alkoxyC2-3alkyl), and R16 is H, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy). A method for preparing I comprises reacting II where X, R8 and R9 are as defined above, R1', R2', R3', R4' are groups R1, R2, R3, R4 as defined above resp., or precursors thereof; and R85 is a leaving group, with HCR6:CR7C(O)R5', where R6 and R7 are as defined above, R5' is a group R5 as defined above or a precursor group therefore; and thereafter if desired or necessary, converting any precursor groups R1', R2', R3', R4' or R5' to groups R1, R2, R3, R4 or R5 resp., or changing a group R5 to a different such group. The compds. of the invention inhibit the serine/threonine kinase activity of the aurora 2 kinase and thus inhibit the cell cycle and cell proliferation. Procedures for assessing these properties are described and test results are given for (E)-4-[4-(2-(3-methylcyclohexylaminocarbonyl)ethenyl)anilino]-6,7-dimethoxyquinazoline.

IT **331734-29-3P**, (E)-4-[4-(2-Carboxyethenyl)anilino]-6,7-dimethoxyquinazoline **331734-31-7P**, (E)-4-[4-(2-Carboxyethenyl)anilino]-6-methoxy-7-(2,2,2-trifluoroethoxy)quinazoline hydrochloride
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazoline derivs., method of preparation and use
in inhibiting aurora 2 kinase)

RN 331734-29-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-31-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, hydrochloride, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



●x HCl

IT **331733-89-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs., method of preparation and use in inhibiting
aurora 2 kinase)
RN 331733-89-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **331733-38-1P 331733-40-5P 331733-41-6P**
331733-43-8P 331733-44-9P 331733-46-1P
331733-48-3P 331733-50-7P 331733-52-9P
331733-53-0P 331733-55-2P 331733-57-4P
331733-59-6P 331733-61-0P 331733-64-3P
331733-68-7P 331733-71-2P 331733-75-6P
331733-77-8P 331733-79-0P 331733-80-3P

331733-81-4P 331733-82-5P 331733-83-6P
331733-84-7P 331733-85-8P 331733-86-9P
331733-87-0P 331733-88-1P 331733-90-5P
331733-91-6P 331733-92-7P 331733-93-8P
331733-94-9P 331733-95-0P 331733-96-1P
331733-97-2P 331733-98-3P 331733-99-4P
331734-00-0P 331734-01-1P 331734-02-2P
331734-03-3P 331734-04-4P 331734-05-5P
331734-06-6P 331734-07-7P 331734-08-8P
331734-09-9P 331734-10-2P 331734-11-3P
331734-12-4P 331734-13-5P 331734-14-6P
331734-15-7P 331734-16-8P 331734-17-9P
331734-19-1P 331734-20-4P 331734-21-5P
331734-22-6P 331734-23-7P 331734-24-8P
331734-25-9P 331734-26-0P 331734-27-1P,
(E)-4-[4-(2-Carboethoxyethenyl)anilino]-6,7-dimethoxyquinazoline
331734-28-2P, (E)-4-[4-(2-Carboethoxyethenyl)phenoxy]-6,7-dimethoxyquinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs., method of preparation and use in inhibiting
aurora 2 kinase)

RN 331733-38-1 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-phenyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-40-5 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-ethyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-41-6 CAPLUS
CN Morpholine, 4-[(2E)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-43-8 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(4-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-44-9 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(1,3-dimethylbutyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-46-1 CAPLUS
CN 2-Propenamide, N-[(2-chlorophenyl)methyl]-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-48-3 CAPLUS
CN 2-Propenamide, N-(2,3-dihydroxypropyl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-50-7 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methylpropyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-52-9 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methylpentyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-53-0 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methoxyethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-55-2 CAPLUS
CN 2-Propenamide, N-(cyanomethyl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-57-4 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-[3-(dimethylamino)propyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-59-6 CAPLUS

CN 2-Propenamide, N-butyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-61-0 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methoxy-1-methylethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-64-3 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(3-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-68-7 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(3-methylcyclohexyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-71-2 CAPLUS
CN 2-Propenamide, N-(2,3-dihydro-1H-inden-2-yl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-75-6 CAPLUS
CN 2-Propenamide, N-(4-chlorotetrahydro-1,1-dioxido-3-thienyl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-77-8 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-[(5-methyl-2-furanyl)methyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-79-0 CAPLUS
CN 2-Propenamide, N-cyclopropyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-80-3 CAPLUS
CN 2-Propenamide, N-cyclobutyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-81-4 CAPLUS
CN 2-Propenamide, N-cyclopentyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-82-5 CAPLUS
CN 2-Propenamide, N-cyclohexyl-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-83-6 CAPLUS
CN Piperidine, 1-[(2E)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-1-oxo-2-propenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-84-7 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-3-pyridinyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-85-8 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methoxyphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-86-9 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(2-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-87-0 CAPLUS
CN 2-Propenamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-N-(3-methoxyphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-88-1 CAPLUS
CN 2-Propenamide, N-(4-chlorophenyl)-3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-90-5 CAPLUS
CN 2-Propenamide, N-(cyclohexylmethyl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-91-6 CAPLUS
CN 2-Propenamide, N-(6-chloro-3-pyridinyl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-92-7 CAPLUS
CN 2-Propenamide, N-(2-furanylmethyl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-93-8 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-[(tetrahydro-2-furanyl)methyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-94-9 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-2-pyridinyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-95-0 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-3-pyridinyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-96-1 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(2-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-97-2 CAPLUS
CN 2-Propenamide, N-(1,3-dimethylbutyl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-98-3 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(2,2,2-trifluoroethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331733-99-4 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(2-methylpropyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-00-0 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(2-methylpentyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-01-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[6-methoxy-7-(phenylmethoxy)-4-quinazolinyl]amino]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-02-2 CAPLUS
CN 2-Propenamide, N-(2,3-dihydro-1H-inden-2-yl)-3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-03-3 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-[2-(2-thienyl)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-04-4 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-[(5-methyl-2-furanyl)methyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—Me

RN 331734-05-5 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-06-6 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-N-[2-(methylthio)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-07-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]amino]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-08-8 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-[2-(methylthio)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-09-9 CAPLUS
CN 2-Propenamide, N-cyclopentyl-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-10-2 CAPLUS
CN 2-Propenamide, N-cyclohexyl-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-11-3 CAPLUS
CN 2-Propenamide, N-(cyclohexylmethyl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-12-4 CAPLUS
CN 2-Propenamide, N-(6-chloro-3-pyridinyl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-13-5 CAPLUS
CN 2-Propenamide, N-(2-furanylmethyl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-14-6 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-[(tetrahydro-2-furanyl)methyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-15-7 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-3-pyridinyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-16-8 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(2-methylphenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-17-9 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(2,2,2-trifluoroethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-19-1 CAPLUS
CN 2-Propenamide, N-(2,3-dihydroxypropyl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-20-4 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(2-methylpentyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-21-5 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(3-methylcyclohexyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-22-6 CAPLUS

CN 2-Propenamide, N-(2,3-dihydro-1H-inden-2-yl)-3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-23-7 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-[2-(2-thienyl)ethyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-24-8 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-25-9 CAPLUS
CN 2-Propenamide, 3-[4-[[6-methoxy-7-(2,2,2-trifluoroethoxy)-4-quinazolinyl]amino]phenyl]-N-(phenylmethyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-26-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, ethyl ester, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-27-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331734-28-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:228864 CAPLUS
DOCUMENT NUMBER: 134:252355
TITLE: Preparation of quinazolines as aurora 2 kinase inhibitors
INVENTOR(S): Mortlock, Andrew Austen; Keen, Nicholas John
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021594	A1	20010329	WO 2000-GB3556	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2384282	AA	20010329	CA 2000-2384282	20000918
BR 2000014133	A	20020611	BR 2000-14133	20000918
TR 200200749	T2	20020621	TR 2002-200200749	20000918
EP 1218356	A1	20020703	EP 2000-962677	20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003509497	T2	20030311	JP 2001-524973	20000918
EE 200200149	A	20030415	EE 2002-149	20000918
AU 763242	B2	20030717	AU 2000-74325	20000918
ZA 2002001833	A	20030605	ZA 2002-1833	20020305
BG 106491	A	20021229	BG 2002-106491	20020307
NO 2002001401	A	20020521	NO 2002-1401	20020320
PRIORITY APPLN. INFO.:			GB 1999-22152 A	19990921
			GB 1999-22156 A	19990921
			GB 1999-22159 A	19990921
			WO 2000-GB3556 W	20000918

OTHER SOURCE(S): MARPAT 134:252355
GI



I



II

AB Title compds. (I) [wherein X = O, S, SO, SO2, NH, or NR8; R8 = H or alkyl; Ra = (un)substituted 3-quinolinyl or Ph; R1-R4 = independently halo, CN, NO2, alkylsulfanyl, N(OH)R12, or R14X1; R12 = H or alkyl; X1 = a direct bond, O, CH2, OC(O), CO, S, SO, SO2, or (un)substituted NHCO, CONH, SO2NH, NHSO2, or NH; R14 = H or (un)substituted hydrocarbyl, heterocyclyl, or alkoxy; or a salt, ester, or amide thereof] were prepared as aurora 2 kinase inhibitors for the treatment of proliferative diseases, such as cancer. For example, 4-phenoxyaniline•HCl and 4-chloro-6-methoxy-7-(3-morpholinopropoxy)quinazoline were refluxed in i-PrOH to yield II (86%). The latter inhibited the serine/threonine kinase activity of aurora 2 kinase by 50% at a concentration of 0.069 μM. In addition, II gave 50% inhibition of MCF-7 cell proliferation at 2.89 μM and reduced BrdU incorporation into cellular DNA by 50% at 3.68 μM.

IT **330999-73-0**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of 4-substituted quinazoline aurora 2 kinase inhibitors for treatment of cancer and other proliferative diseases)

RN 330999-73-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT